With ties to University of Connecticut and, as the firm has proceeded, also to other major players in related space, MAKScientific is building out on the research of the Founder of the firm into the chemistry and biochemistry of the cannabinoid system. Structured around addressing how cannabinergic compound development can address major unmet medical needs for various diseases while also offering clear competitive advantage over present therapies, the firm's mission is the discovery, development and commercialization of novel therapeutics that modulate the endocannabinoid system: a key regulator of homeostasis. MAKScientific asscoiated personnel have expertise in the endocannainoid biochemical pathways and validated therapeutic targets to include two known GPCRs (CB1 and CB2) as well as enzymes that are in the modulation of this biochemical system including fatty acid amide hydrolase (FAAH), N-acylethanolamine-hydrolyzing amidase (NAAA), diacylglycerol lipase (DGL), and monoacylglyceral lipase (MGL) as well as the cannabinoid transporter system. The Company has proficiency in medicinal chemistry and drug design and has substantial drug development assets that include a large library of carefully designed druggable cannabinergic compounds as well as advanced preclinical drug candidates for treating metabolic disorders, chronic liver disease, pain, neurodegenerative and inflammatory diseases. Recognized in the field of endocannabinoid research and drug development, the Company is developing a pipeline of orally available small molecule drugs that target important intervention points in the endocannabinoid system. These targets include the known cannabinoid receptors (CB1 and CB2) as well as key enzymes involved in modulating the system including fatty acid amide hydrolase (FAAH), monoacylglyceral lipase (MGL), N-acylethanolamine-hydrolyzing amidase (NAAA), diacylglycerol lipase (DGL) as well as the cannabinoid transporter system. The Company has several ongoing collaborations with industry, government and academia which have supported expansion of its drug portfolio to include a library of rationally designed and druggable cannabinergic compounds. Selected compounds are being advanced for the treatment of chronic liver disease and metabolic diseases, multiple sclerosis, neurodegenerative disorders, inflammatory pain, chemotherapy induced neuropathy and drug addiction.
